Table of Contents

• 1.1 List of Tables 6
• 1.2 List of Figures 14

2 Introduction 15

• 2.1 Drug Eluting Stents (DES) Overview 15

3 Products under Development 16

• 3.1 Drug Eluting Stents (DES) - Pipeline Products by Stage of Development 16
• 3.2 Drug Eluting Stents (DES) - Pipeline Products by Territory 17
• 3.3 Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path 18
• 3.4 Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date 19
• 3.5 Drug Eluting Stents (DES) - Ongoing Clinical Trials 20

4 Drug Eluting Stents (DES) - Pipeline Products under Development by Companies 21

• 4.1 Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development 21
• 4.2 Drug Eluting Stents (DES) - Pipeline Products by Stage of Development 23

5 Drug Eluting Stents (DES) Companies and Product Overview 25

• 5.1 Aachen Resonance GmbH Company Overview 25
  • 5.1.1 Aachen Resonance GmbH Pipeline Products & Ongoing Clinical Trials Overview 25
• 5.2 Abbott Vascular Inc Company Overview 26
  • 5.2.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 26
• 5.3 Adcomp Technologies Inc. Company Overview 34
  • 5.3.1 Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 34
• 5.4 Advanced Bifurcation Systems Inc Company Overview 35
  • 5.4.1 Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 35
• 5.5 Aeon Bioscience Company Overview 36
  • 5.5.1 Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview 36
• 5.6 AlviMedica Medical Technologies Inc Company Overview 37
  • 5.6.1 AlviMedica Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 37
• 5.7 B. Braun Melsungen AG Company Overview 45
  • 5.7.1 B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview 45
• 5.8 Biosensors International Group Ltd Company Overview 46
  • 5.8.1 Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 46
• 5.9 Biotronik AG Company Overview 52
  • 5.9.1 Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview 52
• 5.10 Biotronik SE & Co KG Company Overview 69
  • 5.10.1 Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 69
• 5.11 Boston Scientific Corp Company Overview 70
  • 5.11.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 70
• 5.12 Cardionovum GmbH Company Overview 76
  • 5.12.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 76
• 5.13 Cardiorev Pte Ltd (Inactive) Company Overview 79
  • 5.13.1 Cardiorev Pte Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 79
• 5.14 Columbia University Company Overview 80
  • 5.14.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 80
• 5.15 Concept Medical Inc Company Overview 81
  • 5.15.1 Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 81
• 5.16 Cordis Corp Company Overview 85
  • 5.16.1 Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview 85
• 5.17 DISA Vascular (Pty) Ltd Company Overview 88
  • 5.17.1 DISA Vascular (Pty) Ltd Pipeline Products & Ongoing Clinical Trials Overview 88
• 5.18 Elixir Medical Corp Company Overview 89
  • 5.18.1 Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 89
• 5.19 Envision Scientific Pvt Ltd Company Overview 91
  • 5.19.1 Envision Scientific Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 91
• 5.20 I.B.S. S.p.A. Company Overview 93
  • 5.20.1 I.B.S. S.p.A. Pipeline Products & Ongoing Clinical Trials Overview 93

6 Drug Eluting Stents (DES)- Recent Developments 161

• 6.1 Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019 161
• 6.2 Nov 14, 2019: Medtronic highlights leadership in inclusion, diversity, and equity in 2019 integrated performance report 163
• 6.3 Nov 13, 2019: Abbott announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020 164
• 6.4 Oct 30, 2019: Orsiro Coronary Drug-Eluting Stent receives market approval in China 165
• 6.5 Oct 23, 2019: Boston Scientific announces results for third quarter 2019 165

7 Appendix 244

• 7.1 Methodology 244
• 7.2 About GlobalData 247
• 7.3 Contact Us 247

Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2019

Summary

GlobalData's Medical Devices sector report, “Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2019" provides an overview of Drug Eluting Stents (DES) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Drug Eluting Stents (DES) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Drug Eluting Stents (DES) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Drug Eluting Stents (DES) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Drug Eluting Stents (DES) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date